# Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer

> **NCT03647592** · — · UNKNOWN · sponsor: **Hunan Province Tumor Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Erlotinib/Gefitinib combined with Bevacizumab

## Key facts

- **NCT ID:** NCT03647592
- **Lead sponsor:** Hunan Province Tumor Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-06-01
- **Primary completion:** 2024-08-31
- **Final completion:** 2025-12-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03647592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03647592, "Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03647592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*